Europe’s Medicines Question: One-Bloc Negotiation or Country-by-Country Bargaining?

The European Union faces a pivotal choice over how to secure supplies of essential medicines, with lawmakers debating whether Brussels should harness the collective bargaining power of its 450 million citizens or maintain the current system of individual national negotiations with major pharmaceutical suppliers in the United States and China.

Renew Europe’s lead negotiator on pharmaceutical policy, Karin Karlsbro, launched the discussion on 21 May, framing the question as central to the bloc’s future health security. The debate comes as the European Commission prepares to table its Critical Medicines Act in the third quarter of 2026, legislation expected to reshape how Europe procures drugs deemed vital for public health.

The Case for Collective Bargaining

Proponents of EU-level negotiations argue that the bloc’s substantial population gives it considerable leverage in global pharmaceutical markets—but only if Member States present a unified front. Currently, individual countries negotiate separately with suppliers, a fragmented approach that critics say weakens Europe’s hand when facing consolidated American and Chinese pharmaceutical giants.

„Europe’s strength lies in its scale, but we forfeit that advantage when we approach suppliers as 27 separate markets rather than one,” Karlsbro noted during the parliamentary session. „The question is whether we have the political will to act as the economic power we actually are.”

The single-bloc approach would mirror strategies employed in other sectors where the EU has successfully leveraged its market size. Advocates point to the potential for better pricing, more reliable supply guarantees, and stronger negotiating positions during shortage situations. With pharmaceutical supply chains increasingly concentrated in Asia and North America, the argument for consolidation has gained traction since the COVID-19 pandemic exposed vulnerabilities in Europe’s medicines access.

National Sovereignty Concerns

Yet the proposal faces significant headwinds from Member States wary of ceding control over health policy, an area that remains largely within national competence under EU treaties. Several governments have expressed concern that a one-size-fits-all negotiating strategy might not reflect differing national priorities, healthcare systems, or budgetary constraints.

The debate touches on fundamental questions about the balance between EU coordination and national autonomy. Healthcare provision varies considerably across the bloc, from the Nordic model to Mediterranean systems, and countries maintain distinct formularies, reimbursement frameworks, and therapeutic traditions. Critics of centralisation argue these differences make unified negotiations impractical for all but the most critical medicines.

Defining ‘Critical’ Medicines

A key challenge for the forthcoming Critical Medicines Act will be establishing which drugs merit bloc-level procurement. The Commission faces the delicate task of drawing boundaries that command consensus among Member States with divergent healthcare priorities and epidemiological profiles.

Candidates for the critical list likely include antibiotics, vaccines for pandemic preparedness, cancer treatments, and medicines for rare diseases where small patient populations offer little incentive for multiple suppliers. However, expanding the list too far risks recreating the coordination problems the legislation aims to solve, whilst too narrow a definition might leave significant vulnerabilities unaddressed.

Geopolitical Dimensions

The debate unfolds against a backdrop of growing geopolitical tensions and concerns about strategic dependencies. Europe’s reliance on pharmaceutical suppliers in the US and China has emerged as a foreign policy consideration, particularly as both powers have demonstrated willingness to use supply chains as leverage in international disputes.

Collective EU negotiation could serve not merely as a procurement mechanism but as a tool of strategic autonomy, potentially increasing Europe’s ability to withstand external pressure. However, it might also provoke tensions with Washington and Beijing, who may prefer dealing with individual member states rather than a unified European position.

Industry Response

Pharmaceutical manufacturers have watched the debate closely, with industry representatives expressing concern about potential price pressures from consolidated European bargaining. US and Chinese suppliers have built relationships with individual national health systems over decades, and a shift to EU-level negotiations would require substantial adjustments to their commercial strategies.

The European pharmaceutical industry itself remains divided, with generic manufacturers generally more supportive of coordination than innovative drug developers, who worry about implications for pricing and market access across the bloc.

As the Commission refines its legislative proposal ahead of the 2026 deadline, the fundamental question Karlsbro posed will shape not only Europe’s pharmaceutical future but also test the bloc’s capacity for collective action in an area touching national sovereignty. The coming months of consultation and debate will reveal whether Member States can set aside individual interests for the collective bargaining power their combined populations represent—a decision with implications extending well beyond medicines policy to Europe’s broader quest for strategic autonomy.